As 2024 winds down, it’s the perfect time to reflect on the progress we’ve made and plan for an impactful 2025. At Veristat, we pride ourselves on being the trusted partner for biotech companies navigating the complexities of clinical development and regulatory approval. Whether you’re advancing groundbreaking therapies through early clinical trials, preparing for pivotal studies, or finalizing submissions for regulatory approval, our team is here to help you achieve your goals. With expertise in: ✨ Clinical Trial Management ✨ Biostatistics & Data Management ✨ Regulatory Submissions & Strategic Consulting ✨ Medical Writing & Publication Support ✨ Specialized Cell & Gene Therapy Programs We tailor our approach to meet the unique needs of each client, ensuring their success at every stage of development. If you’re strategizing for 2025 and need a partner to help you take the next step, let’s connect. I’d love to share how Veristat can help you bring life-changing therapies to patients. #ClinicalDevelopment #CRO #EndOfYearPlanning #Veristat
Mike Peredna’s Post
More Relevant Posts
-
This year, the biotech world delivered in a big way, particularly in the ATMP and Cell Therapy space. Major strides in CAR-T and allogeneic therapies brought us closer to scalable, off-the-shelf solutions, while CRISPR and gene-editing breakthroughs tackled rare diseases with unprecedented precision. The FDA played a pivotal role in the excitement, with a record number of cell and gene therapies earning approval—including new CAR-T and gene-editing treatments that are reshaping the future of medicine. Investment, although divided in opinon, remained a bright spot, with significant funding fueling biotech SMEs and their bold ideas. From early discovery to clinical programs, the focus on personalized medicine and unmet medical needs has never been stronger. Partnerships between innovators and pharma giants also drove exciting momentum, underscoring the industry’s collaborative spirit. Things are certianly not slowing down for my team at Northreach anytime soon with a number of new ATMP build outs and partnerships agreed for 2025. If you are a Cell Therapy expert in the field of Clinical Operations, Regulatory Affairs and Medical Safety, my colleague Mitzi Sanderson and I would love to hear from you. #biotech #atmp #celltherapy #ATMP
To view or add a comment, sign in
-
Clinical trials are a critical part of the transition into the clinical stage. 🚀I know how challenging it can be to manage complex clinical trials. 🌐They involve multiple stakeholders, stringent regulations, and complex protocols. The Chief Medical Officer has to ensure that the clinical trials are designed and the Head of Clinical Operations ensures they are executed correctly, whereas both can be a daunting task. 💉Oncology and cell and gene therapy clinical trials often involve complex designs, such as platform or umbrella designs. These clinical trials allow efficient, parallel evaluation of multiple targeted therapies in relatively small biologically defined patient sub-populations. However, they can be challenging to operationalize. ⁉How can we overcome these challenges and ensure the success of our clinical trials? Here are some tips that I have learned from my experience: - Planning and Designing: Carefully plan and design the trial. This includes defining the objective, determining the sample size, and deciding on the randomization and blinding methods. - Regulatory Compliance: Ensure compliance with regulatory requirements. This includes obtaining necessary approvals from ethical committees and regulatory bodies. - Protocol Development: Develop a detailed protocol that outlines the study design, methodology, statistical considerations, and organization of the study. - Data Management: Implement robust data management practices. This includes data collection, data entry, data cleaning, and data storage. - Site Selection and Management: Select appropriate sites for the trial and manage them effectively. This includes training site staff, monitoring site performance, and ensuring patient recruitment and retention. - Risk Management: Identify potential risks and develop strategies to mitigate them. This includes monitoring safety data, managing adverse events, and implementing quality control measures. - Communication: Maintain clear and effective communication with all stakeholders. This includes regular updates to the trial team, the sponsor, the regulatory bodies, and the participants. - Analysis and Reporting: Analyze the data using appropriate statistical methods and report the results in a clear and transparent manner. Please share your experience and COMMENT below. 📢 If you like this post, please 🤝CONNECT WITH ME via LinkedIn. Help me in increasing post reach ➡LIKE or 🌀SHARE. You are interested in more insights? ✅SIGN UP for my Newsletter and Clinical Operations Roundtable. 👉 Clinical Excellence GmbH #ClinicalTrials #ClinicalOperations #leadershipmatters
To view or add a comment, sign in
-
🚀 Genomics : Driving Personalized Medicine Innovation🔬 Download Informative PDF Guide:-https://lnkd.in/di7JSbFa The personalized medicin is booming, offering a wealth of opportunities for industry players. 💡 Pharmaceutical companies are making significant investments in #personalizedmedicineresearch, empowering healthcare providers to tailor treatments based on each patient's unique needs for better outcomes. This targeted approach is shaping the future of #healthcare. 🌱 🔄 Gene therapy advancements are poised to revolutionize treatments, potentially replacing traditional drugs and surgeries by allowing doctors to address disorders by inserting genes directly into a patient’s cells. 💡 Key Partnerships & Developments: - In September 2022, QIAGEN (Germany) and Neuron23 Inc. (US) joined forces to develop a #companiondiagnostic for Neuron23's precision medicine aimed at treating Parkinson’s disease. - In May 2022, Illumina (US) entered a strategic partnership with Janssen to accelerate the development of #precision_medicine by utilizing whole-#genome sequencing (WGS) and multi-omic methodologies. These collaborations highlight the exciting potential of Next-Generation Sequencing (#NGS) in precision medicine and #molecular_diagnostics. 🔬💊 #PersonalizedMedicine #PrecisionMedicine #GeneTherapy #NGS #HealthcareInnovation #Pharmaceuticals #Biotech #MolecularDiagnostics #MedTech
To view or add a comment, sign in
-
At adthera, we are committed to accelerating the delivery of advanced therapy medicinal products (ATMPs) with our unique and integrated approach. Our capabilities span the entire lifecycle of cell and gene therapy development, ensuring that innovative treatments reach patients with speed, efficiency, and the highest quality standards. 📊 Our Core Capabilities: Therasplore™ Development Process: Our platform-agnostic cell therapy development expertise allows us to innovate and refine therapies tailored to specific needs, ensuring robust and scalable solutions. Theramake™ GMP Excellence Manufacturing System: We provide scalable GMP manufacturing capabilities that ensure compliance and quality, leveraging state-of-the-art facilities to bring your cell therapy products to life. Theraconsult™ Advisory Consulting Platform: Our data-driven analytics optimize quality, processes, and outcomes, providing actionable insights that enhance every stage of therapy development and manufacturing. 🔬 Why Choose Adthera Bio?: Innovative Solutions: Our team combines deep scientific knowledge with cutting-edge technology to push the boundaries of cell and gene therapy. Quality and Compliance: We maintain rigorous standards to ensure every product meets regulatory requirements and delivers optimal patient outcomes. Customer-Centric Approach: We partner closely with biotechs and academic centers, offering personalized solutions that address unique challenges and goals. #cdmo #regenerativemedicine #digitalfirst #celltherapy #immunotherapy #innovation #processdevelopment #continousimprovement #gmp #clinicaltrials #atmp #advancedtherapies #personalizedmedicine #gxp #optimization #automation #bestinclass #rightfirsttime #celltherapymanufacturing #innovation #digital #partnerships #collaboration #networking #digitaltransformation #quailtycontrol #qualityassurance #GMP #simulation #manufacturing #processdevelopment
To view or add a comment, sign in
-
It's here. FDA's LDT Final Rule: FDA changed the scope of the phase-in of the rule. The Proposed Rule preamble described a broad-reaching removal of enforcement discretion over the vast majority of laboratory based diagnostic tests, but the Final Rule preamble contemplates significant grandfathering, additional categories of enforcement discretion that will remain operative, and the opportunity for third-party review processes. We are fielding TONS of inquiries about the impact of this rule across the diagnostic industry. The impact is far and wide, touching therapeutic development (think biomarkers and companion diagnostics), precision medicine (think chemotherapy and gene therapy), and direct patient care (think access and equity). 🔬 Will marketing applications be required? What are the timelines? 🔬 Does the developer need to register and list? Comply with GMPs and QSR? Submit MDRs? Maintain a complaint system? Manage a CAPA program? 🔬 Design controls on a lab based diagnostic test? Yikes! 🔬 Supplier controls? Wait, I buy everything RUO? 😨 See comment below ⬇ for link to the full article, and flip below ➡ for a quick overview and key questions we are assessing for clients. Yes, your Board needs to understand this. Reach out if you need a presentation guide (LDT developer, RUO developer, and Investor/Fund). DLA Piper Life Sciences Sector @thejoyfullawyer
To view or add a comment, sign in
-
LDT final rule from FDA is here. Reach out to understand how it impacts your organization.
It's here. FDA's LDT Final Rule: FDA changed the scope of the phase-in of the rule. The Proposed Rule preamble described a broad-reaching removal of enforcement discretion over the vast majority of laboratory based diagnostic tests, but the Final Rule preamble contemplates significant grandfathering, additional categories of enforcement discretion that will remain operative, and the opportunity for third-party review processes. We are fielding TONS of inquiries about the impact of this rule across the diagnostic industry. The impact is far and wide, touching therapeutic development (think biomarkers and companion diagnostics), precision medicine (think chemotherapy and gene therapy), and direct patient care (think access and equity). 🔬 Will marketing applications be required? What are the timelines? 🔬 Does the developer need to register and list? Comply with GMPs and QSR? Submit MDRs? Maintain a complaint system? Manage a CAPA program? 🔬 Design controls on a lab based diagnostic test? Yikes! 🔬 Supplier controls? Wait, I buy everything RUO? 😨 See comment below ⬇ for link to the full article, and flip below ➡ for a quick overview and key questions we are assessing for clients. Yes, your Board needs to understand this. Reach out if you need a presentation guide (LDT developer, RUO developer, and Investor/Fund). DLA Piper Life Sciences Sector @thejoyfullawyer
To view or add a comment, sign in
-
🌍🧬 Streamline Your Cell & Gene Therapy Clinical Trials with TecEx Medical With the cell & gene therapy market projected to grow to $93.78 Billion by 2030, ensuring efficient clinical trials is crucial for biotech success. Delays in trial timelines can significantly impact market entry and revenue potential. Why Partner with TecEx Medical? ✅ Compliance Assurance: From regulatory approvals to customs clearance, our Importer of Record (IoR) services guarantee seamless logistics, ensuring that clinical supplies and ancillaries are never late! ✅ Global Customs Expertise: We've reduced import license times by 46%, ensuring swift deployment of trial commodities worldwide. ✅ Global Reach: Our tailored logistics and compliance solutions span complex regions like the Americas and Asia-Pacific, handling everything from investigational products to medical devices with precision. Let's Accelerate Your Trials Partner with TecEx Medical to navigate the complexities of cell & gene therapy clinical trials effortlessly. #ClinicalResearch #CellAndGeneTherapy #ImporterOfRecord #GlobalLogistics #CASS #clinicalsupplies
To view or add a comment, sign in
-
Gene therapies are challenging to bring to market. New therapeutic modalities require partnership across a set of stakeholders to get to market efficiently. Learn how Danaher Life Sciences can help: https://bit.ly/4acTgWu #DanaherLifeSciences #SpeedofLife #genetherapy #ASGCT
To view or add a comment, sign in
-
Exciting news in the world of biotech! Pfizer has just achieved a significant milestone with the FDA approval of its groundbreaking gene therapy. This breakthrough treatment holds immense promise for patients battling challenging genetic conditions, marking a remarkable advancement in medical science. It's inspiring to witness the tireless dedication of Pfizer's researchers and scientists, whose relentless pursuit of innovation has led to this pivotal moment. Their commitment to pushing the boundaries of what's possible in healthcare exemplifies the spirit of progress and determination. However, it's essential to acknowledge the complexities involved in bringing such transformative therapies to market. The investment of time, resources, and expertise required for research, development, and regulatory approval is substantial. As a result, the cost of these treatments reflects the extensive efforts and rigorous standards upheld throughout the process. While the reported price of $3.5 million for Pfizer's gene therapy may raise eyebrows, it's crucial to recognize the value it brings in terms of potentially life-changing outcomes for patients and their families. Additionally, advancements in gene therapy hold the promise of paving the way for more accessible and affordable treatments in the future, as technology evolves and economies of scale come into play. As we celebrate this milestone, let's also keep the conversation going about how we can work collaboratively to ensure that groundbreaking therapies like this one reach those who need them most, while also striving for greater accessibility and affordability in healthcare. #Pfizer #GeneTherapy #MedicalInnovation #FDAApproval #Healthcare #Biotech #Science #Innovation #Pharmacist
To view or add a comment, sign in
-
Organizations that seamlessly blend scientific expertise with a clear CMC strategy are better equipped to navigate the complexities of cell therapy development. This approach allows for early anticipation of challenges, proactive solutions, and efficient progress—without compromising quality or safety. At weCANdev, we embody this by supporting your journey with our development lab and offering: 1. De-risking Innovation – We integrate process, analytical, and pre-clinical development strategies with our partners' regulatory expertise from day one. This alignment ensures that experiments meet CMC requirements early on, enhances compliance, and identifies potential bottlenecks—reducing costly delays later in development and venture formation. 2. Enhanced Information Flow – As both wet lab scientists and consultants, we create a unique, data-driven feedback loop. By integrating real-time insights from our lab with our QbD-driven CMC strategy, we enable teams to make informed decisions and adapt quickly to the challenges of cell and gene therapy development. 3. Streamlined Workflows – Our integrated roles foster a dynamic environment for creative problem-solving. Through close collaboration, we drive innovative solutions that push boundaries, delivering better outcomes for our clients. Let’s connect and explore how we can accelerate your projects. #CellAndGeneTherapy #CMC #Biotech
To view or add a comment, sign in